Engagement with the HCV care cascade among high-risk groups: A population-based study

被引:6
作者
Erman, Aysegul [1 ,2 ,8 ]
Everett, Karl [2 ]
Wong, William W. L. [1 ,2 ,3 ]
Forouzannia, Farinaz [3 ]
Greenaway, Christina [4 ]
Janjua, Naveed [5 ]
Kwong, Jeffrey C. [2 ,6 ]
Sander, Beate [1 ,2 ,7 ]
机构
[1] Univ Hlth Network, Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada
[2] ICES, Toronto, ON, Canada
[3] Univ Waterloo, Sch Pharm, Kitchener, ON, Canada
[4] McGill Univ, Jewish Gen Hosp, Div Infect Dis, Montreal, PQ, Canada
[5] British Columbia Ctr Dis Control BCDC, Vancouver, BC, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] Publ Hlth Ontario, Toronto, ON, Canada
[8] Univ Hlth Network, Toronto Gen Hosp, Toronto Hlth Econ & Technol Assessment THETA Colla, Eaton Bldg,10th Floor,200 Elizabeth St, Toronto, ON M5G 2C4, Canada
关键词
HEPATITIS-C;
D O I
10.1097/HC9.0000000000000222
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: HCV elimination requires a thorough understanding of the care cascade. A direct-acting antiviral (DAA)-era description of the care cascade has not been undertaken in Ontario, Canada's most populous jurisdiction. Our primary objective was to describe the current population-level care cascade in the general Ontario population and among key risk groups - baby boomers, immigrants, and individuals experiencing residential instability. The secondary objective was to identify predictors of engagement. Methods: We conducted a population-based cohort study of Ontario residents undergoing HCV testing between January 1, 1999, and December 31, 2018, and mapped the care cascade [antibody-diagnosed, RNA tested, RNA positive, genotyped, treated, achieved sustained virologic response, reinfected/relapsed] as of December 31, 2018. The cascade was stratified by risk groups. Cause-specific hazard modeling was used to identify demographic, and socioeconomic predictors of engagement with key steps of the cascade. Results: Among 108,428 Ontario residents living with an HCV antibody diagnosis, 88% received confirmatory RNA testing; of these, 62% tested positive and 94% of positive tests were genotyped. Of those with confirmed viremia, 53% initiated treatment and 76% of treated individuals achieved sustained virologic response, while similar to 1% experienced reinfection or relapse. Males, older birth cohorts, long-term residents, those with a history of substance use disorder and social marginalization (eg, material deprivation, residential instability), and those initially diagnosed in the pre-DAA era exhibited lower rates of engagement with almost every step of HCV care. Conclusions: Despite DAA era improvements, treatment initiation remains a major gap. HCV screening and linkage-to-treatment, particularly for those with a history of substance use disorder and social marginalization, will be needed to equitably close gaps in HCV care in the province.
引用
收藏
页数:16
相关论文
共 22 条
  • [1] The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals
    Bartlett, Sofia R.
    Yu, Amanda
    Chapinal, Nuria
    Rossi, Carmine
    Butt, Zahid
    Wong, Stanley
    Darvishian, Maryam
    Gilbert, Mark
    Wong, Jason
    Binka, Mawuena
    Alvarez, Maria
    Tyndall, Mark
    Krajden, Mel
    Janjua, Naveed Z.
    [J]. LIVER INTERNATIONAL, 2019, 39 (12) : 2261 - 2272
  • [2] Impact of COVID-19-related public health measures on HCV testing in British Columbia, Canada: An interrupted time series analysis
    Binka, Mawuena
    Bartlett, Sofia
    Velasquez Garcia, Hector A.
    Darvishian, Maryam
    Jeong, Dahn
    Adu, Prince
    Alvarez, Maria
    Wong, Stanley
    Yu, Amanda
    Samji, Hasina
    Krajden, Mel
    Wong, Jason
    Janjua, Naveed Z.
    [J]. LIVER INTERNATIONAL, 2021, 41 (12) : 2849 - 2856
  • [3] Cooper CL., 2020, BMC PUBLIC HLTH, V20, P1
  • [4] Peer Support Models for People With a History of Injecting Drug Use Undertaking Assessment and Treatment for Hepatitis C Virus Infection
    Crawford, Sione
    Bath, Nicky
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 : S75 - S79
  • [5] Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs
    Cunningham, Evan B.
    Hajarizadeh, Behzad
    Amin, Janaki
    Hellard, Margaret
    Bruneau, Julie
    Feld, Jordan J.
    Cooper, Curtis
    Powis, Jeff
    Litwin, Alain H.
    Marks, Philippa
    Dalgard, Olav
    Conway, Brian
    Moriggia, Alberto
    Stedman, Catherine
    Read, Phillip
    Bruggmann, Philip
    Lacombe, Karine
    Dunlop, Adrian
    Applegate, Tanya L.
    Matthews, Gail, V
    Fraser, Chris
    Dore, Gregory J.
    Grebely, Jason
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (08) : 1392 - 1400
  • [6] The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach
    Erman, Aysegul
    Wong, William W. L.
    Feld, Jordan J.
    Grootendorst, Paul
    Krahn, Murray D.
    [J]. LIVER INTERNATIONAL, 2020, 40 (01) : 51 - 59
  • [7] Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies
    Hamadeh, Abdullahi
    Haines, Alex
    Feng, Zeny
    Thein, Hla-Hla
    Janjua, Naveed Z.
    Krahn, Murray
    Wong, William W. L.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2020, 27 (12) : 1419 - 1429
  • [8] Challenges in administrative data linkage for research
    Harron, Katie
    Dibben, Chris
    Boyd, James
    Hjern, Anders
    Azimaee, Mahmoud
    Barreto, Mauricio L.
    Goldstein, Harvey
    [J]. BIG DATA & SOCIETY, 2017, 4 (02):
  • [9] hopkinsacg, J HOPKINS ACG SYST
  • [10] The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)
    Janjua, Naveed Z.
    Kuo, Margot
    Yu, Amanda
    Alvarez, Maria
    Wong, Stanley
    Cook, Darrel
    Wong, Jason
    Grebely, Jason
    Butt, Zahid A.
    Samji, Hasina
    Ramji, Alnoor
    Tyndall, Mark
    Krajden, Mel
    [J]. EBIOMEDICINE, 2016, 12 : 189 - 195